The Technical Analyst
Intersect Ent Inc [XENT]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Intersect Ent Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $28.24
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-08-05 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.54 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.05x |
| Company: PE -10.54 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 28.10 - 28.38 ( +/- 0.49%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-13 | Meier Richard A | Sell | 57 230 | Common Stock |
| 2022-05-13 | Meier Richard A | Sell | 65 759 | Common Stock |
| 2022-05-13 | Meier Richard A | Sell | 40 607 | Common Stock |
| 2022-05-13 | Meier Richard A | Sell | 34 000 | Stock Options (Right to buy) |
| 2022-05-13 | Meier Richard A | Sell | 74 852 | Stock Options (Right to buy) |
| INSIDER POWER |
|---|
| -100.00 |
| Last 98 transactions |
| Buy: 482 629 | Sell: 874 745 |
Forecast:
01:40 - $27.99
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $28.24 (0.00% ) |
| Volume | 0 mill |
| Avg. Vol. | 0.439 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XENT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
XENT
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Latest Press Releases
2021-12-14 07:00:00 - Press Release
Orthofix Announces Appointment Of Thomas A. West To Board Of Directors
Lewisville, texas--(business wire)--orthofix names thomas a. west to the company's board of directors and appoints him to the compensation and talent development committee.
2021-09-13 15:23:00 - Press Release
Shareholder Alert: Monteverde & Associates Pc Announces An Investigation Of Intersect Ent, Inc. - Xent
New york, sept. 13, 2021 /prnewswire/ -- juan monteverde , founder and managing partner at monteverde & associates pc, a national securities firm rated top 50 in the 2018-2020 iss securities class action services report and headquartered at the empire state building in new york city, is investigating intersect ent, inc. ("xent" or the "company") (xent) relating to its proposed acquisition by medtronic plc.
2021-08-09 14:47:00 - Press Release
Alert: Rowley Law Pllc Is Investigating Proposed Acquisition Of Intersect Ent, Inc.
New york, aug. 9, 2021 /prnewswire/ -- rowley law pllc is investigating potential securities law violations by intersect ent, inc. (nasdaq: xent) and its board of directors concerning the proposed acquisition of the company by medtronic plc (nyse: mdt). stockholders will receive $28.25 for each share of intersect ent stock that they hold.
2021-08-06 16:31:00 - Press Release
Shareholder Alert: Weisslaw Llp Investigates Intersect Ent, Inc.
New york, aug. 6, 2021 /prnewswire/ -- weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of intersect ent, inc. ("intersect" or the "company") (nasdaq: xent) in connection with the proposed acquisition of the company by medtronic plc ("medtronic") (nyse:mdt). under the terms of the merger agreement, the company's shareholders will receive $28.25 per share in cash for each share of intersect common stock that they hold.
2021-08-06 12:45:00 - Press Release
Intersect Ent Merger Investigation: Halper Sadeh Llp Announces Investigation Into Whether The Sale Of Intersect Ent, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm – Xent
New york--(business wire)--halper sadeh llp, a global investor rights law firm, is investigating whether the sale of intersect ent, inc. (nasdaq: xent) to medtronic plc for $28.25 per share is fair to intersect ent shareholders. halper sadeh encourages intersect ent shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whether inters
Latest News
2022-05-10 12:48:16 - Zacks Investment Research
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates
Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.
2021-12-02 13:04:48 - Zacks Investment Research
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
2021-11-18 12:14:16 - Zacks Investment Research
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
2021-09-30 11:08:41 - Zacks Investment Research
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
2021-09-13 15:23:00 - PRNewsWire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Intersect ENT, Inc. ("XENT" or the "Company") (XENT) relating to its proposed acquisition by Medtronic plc.
2021-08-09 14:47:00 - PRNewsWire
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed acquisition of the company by Medtronic plc (NYSE: MDT). Stockholders will receive $28.25 for each share of Intersect ENT stock that they hold.
2021-08-09 12:23:15 - Zacks Investment Research
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
2021-08-07 22:39:46 - Pulse2
Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion
Medtronic plc (NYSE:MDT) announced it entered into a definitive agreement with Intersect ENT (NASDAQ: XENT) for $1.1 billion. The post Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion appeared first on Pulse 2.0.
2021-08-06 16:31:00 - PRNewsWire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intersect ENT, Inc. ("Intersect" or the "Company") (NASDAQ: XENT) in connection with the proposed acquisition of the Company by Medtronic plc ("Medtronic") (NYSE:MDT). Under the terms of the merger agreement, the Company's shareholders will receive $28.25 per share in cash for each share of Intersect common stock that they hold.
2021-08-06 16:22:10 - The Motley Fool
Why Intersect ENT Shot 12% Higher on Friday
